Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Harry La Janssen"'
Autor:
Surain B. Roberts, Woo Jin Choi, Lawrence Worobetz, Catherine Vincent, Jennifer A. Flemming, Angela Cheung, Karim Qumosani, Mark Swain, Dusanka Grbic, Hin Hin Ko, Kevork M. Peltekian, Lusine Abrahamyan, Monika Saini, Kattleya Tirona, Bishoi Aziz, Ellina Lytvyak, Pietro Invernizzi, Cyriel Y. Ponsioen, Tony Bruns, Nora Cazzagon, Keith Lindor, George N. Dalekos, Nikolaos K. Gatselis, Xavier Verhelst, Annarosa Floreani, Christophe Corpechot, Marlyn J. Mayo, Cynthia Levy, Maria-Carlota Londoño, Pier M. Battezzati, Albert Pares, Frederik Nevens, Adriaan van der Meer, Kris V. Kowdley, Palak J. Trivedi, Ana Lleo, Douglas Thorburn, Marco Carbone, Nazia Selzner, Aliya F. Gulamhusein, Harry LA. Janssen, Aldo J. Montano-Loza, Andrew L. Mason, Gideon M. Hirschfield, Bettina E. Hansen
Publikováno v:
JHEP Reports, Vol 6, Iss 10, Pp 101168- (2024)
Background & Aims: Biochemical response to ursodeoxycholic acid (UDCA) therapy is associated with good prognosis in people living with primary biliary cholangitis (PBC). Biochemical response is typically assessed early in disease and it is not known
Externí odkaz:
https://doaj.org/article/8d1c44ac78ae4a3ebc2eca8571c39ace
Autor:
Jurriën GP Reijnders, Harry LA Janssen
Publikováno v:
Infection and Drug Resistance, Vol 2009, Iss default, Pp 13-26 (2009)
Jurriën GP Reijnders, Harry LA JanssenDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, The NetherlandsAbstract: In the field of HIV management, tenofovir disoproxil fumarate (TDF) plays a pivotal role and h
Externí odkaz:
https://doaj.org/article/0c2e8fb24e23466c90a5f796d31fe438
Autor:
Angela C Cheung, Aldo Montano-Loza, Mark Swain, Catherine Vincent, Eberhard Renner, Morris Sherman, Harry LA Janssen, Andrew L Mason
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 29, Iss 6, Pp 293-293 (2015)
Externí odkaz:
https://doaj.org/article/dd054c911428476cb935386c33d49464
Autor:
Fiorella Murillo Perez, Femi Adekunle, Tracy Mayne, Elizabeth Malecha, Eric Ness, Adriaan J Van Der Meer, Willem J Lammers, Palak J Trivedi, Pier Maria Battezzati, Frederik Nevens, Kris V Kowdley, Tony Bruns, Nora Cazzagon, Annarosa Floreani, Andrew L Mason, Albert Parés, Maria Londoño, Pietro Invernizzi, Marco Carbone, Ana Lleo, Marlyn J Mayo, George N Dalekos, Nikolaos K Gatselis, Douglas Thorburn, Xavier Verhelst, Aliya Gulamhusein, Harry LA Janssen, Michael Trauner, Christopher Bowlus, Keith D Lindor, Christophe Corpechot, Gideon Hirschfield, Bettina E Hansen
Publikováno v:
Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1399c17bcc5071c7d91ed2a04f0271b7
https://doi.org/10.1136/gutjnl-2022-basl.60
https://doi.org/10.1136/gutjnl-2022-basl.60
Autor:
Jordan J. Feld, Wendy C. King, Marc G. Ghany, Kyong-Mi Chang, Norah Terrault, Robert P. Perrillo, Mandana Khalili, Amanda S. Hinerman, Harry LA. Janssen, Anna S. Lok
Publikováno v:
Clinical Gastroenterology and Hepatology. 21:1503-1512.e4
Most patients in the immunotolerant (IT) phase of chronic hepatitis B (CHB) transition to the immune active (IA-hepatitis B surface antigen [HBeAg]+) phase by early adulthood. We examined characteristics of adults in the IT vs IA-HBeAg+ phase and rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34b92d5db08b03c5fa495e1bad65cec
https://doi.org/10.1016/j.cgh.2022.06.015
https://doi.org/10.1016/j.cgh.2022.06.015
Autor:
Mia J Biondi, Grishma Hirode, Camelia Capraru, Aaron Vanderhoff, Joel Karkada, Brett Wolfson-Stofko, David Smookler, Steven M Friedman, Kathy Bates, Tony Mazzulli, Joshua V Juan, Hemant Shah, Bettina E Hansen, Jordan J Feld, Harry LA Janssen
Publikováno v:
Can Liver J
BACKGROUND: Widespread screening and treatment of hepatitis C virus (HCV) is required to decrease late-stage liver disease and liver cancer. Clinical practice guidelines and Canadian Task Force on Preventative Health Care recommendations differ on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd870d245002192e0b7bfee5201fb3b
https://europepmc.org/articles/PMC9473558/
https://europepmc.org/articles/PMC9473558/
Autor:
Sang Hoon Ahn, Giulio Marchesini, Carla S. Coffin, Wan-Long Chuang, Aric J. Hui, Yi-Hsang Huang, Yang Zhao, Susanna K. Tan, Tak Yin Owen Tsang, Magdy Elkhashab, Sayed-Mohammed Jafri, Chien-Hung Chen, Harry La Janssen, Jeong Heo, John F. Flaherty, Diana M. Brainard, Claire Fournier, Kosh Agarwal, Carol Yee Kwan Chan, Young-Suk Lim, Anuj Gaggar, Edward Gane, Vithika Suri, Pietro Lampertico
Publikováno v:
Clinical Hepatology.
Background We have previously shown in renally impaired (RI) CHB patients, including those with ESRD on HD, that switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters at Wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15afebbf2a4d1d0f6690a80bc2b37cb6
https://doi.org/10.1136/gutjnl-2021-iddf.80
https://doi.org/10.1136/gutjnl-2021-iddf.80
Autor:
Harry La Janssen, Chun-Yen Lin, Aric J. Hui, Huy N. Trinh, Claire Fournier, Yang Zhao, Ho Bae, Vithika Suri, Stephen D. Ryder, John F. Flaherty, Young-Suk Lim, Anuj Gaggar, Carol Yee Kwan Chan, Susanna K. Tan, Dianna M Brainard, Jeong Heo, Wan-Long Chuang, Tak Yin Owen Tsang
Publikováno v:
Clinical Hepatology.
Background We have previously shown that in hepatically impaired CHB patients, switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters through 48 weeks. Here we present our fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9923530515d1ce5de0293f9b7eda7795
https://doi.org/10.1136/gutjnl-2021-iddf.81
https://doi.org/10.1136/gutjnl-2021-iddf.81
Autor:
George N. Dalekos, Jae-Jun Shim, Spilios Manolakopoulos, Han Ah Lee, Harry La Janssen, George V. Papatheodoridis, Fabien Zoulim, Jun Sik Yoon, Pietro Lampertico, Dong Hyun Sinn, Hyoung Su Kim, Heejoon Jang, Yoon Jun Kim, Thomas Berg, Vana Sypsa, Sang Bong Ahn, Soo-Young Park, Sung Eun Kim, Soung Won Jeong, Dae Won Jun, Eileen L. Yoon, Jeong Hoon Lee, Joon Yeul Nam, Myoung-Jin Jang, Yeon Seok Seo, Jung Hwan Yoon, Yun Bin Lee, Ramazan Idilman, Hwi Young Kim, Joo Hyun Sohn, Jose Luis Calleja, Maria Buti, Yong Kyun Cho, John Goulis, Seung Up Kim
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 20(6)
Background & Aims Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC). We investigated the impact of HBeAg st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a4a1e78f672bcdde5a2d127ccef8038
https://pubmed.ncbi.nlm.nih.gov/34500103
https://pubmed.ncbi.nlm.nih.gov/34500103
Autor:
Robert A. de Man, Harry La Janssen, Milan J Sonneveld, Annemiek A. van der Eijk, Andre Boonstra, Zwier M. A. Groothuismink, Boris Jb Beudeker
Publikováno v:
Antiviral Therapy. 25:217-222
Background Serum hepatitis B core-related antigen (HBcrAg) levels refect intrahepatic HBV replication activity. We aimed to study whether HBcrAg levels predict response to pegylated interferon (PEG-IFN) treatment in hepatitis B e antigen (HBeAg)-posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cba23e8bbd0e584b100c62c60f3f1033
https://doi.org/10.3851/imp3367
https://doi.org/10.3851/imp3367